The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Lipid Contract Manufacturing (CMO) Market by Type of Lipid (Liposomes / Lipid Nanoparticles, Phospholipids, PEGylated Lipids, Ionizable Lipids (Cationic / Anionic Lipids), Triglycerides, Sphingolipids, Neutral Lipids, Others), Company Size (Small, Mid-sized and Large / Very Large), Scale of Operation (Preclinical, Clinical and Commercial) and Key Geographical Regions (North America, Europe, Asia Pacific, MENA, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2021

  • Pages
    230

  • View Count
    1708

Example Insights

Lipid-Contract-Manufacturing-Market-Context Lipid-Contract-Manufacturing-Market-List Lipid-Contract-Manufacturing-Market-Distribution Lipid-Contract-Manufacturing-Market-Distribution-by-Location
Lipid-Contract-Manufacturing-Market-Company-Competitiveness-Analysis Lipid-Contract-Manufacturing-Market-Partnerships-and-Collaborations Lipid-Contract-Manufacturing-Market-Recent-Expansions Lipid-Contract-Manufacturing-Market-Technology-Providers
Lipid-Contract-Manufacturing-Market-Company-Capacity-Analysis Lipid-Contract-Manufacturing-Market-Distribution-by-Company-Size    

Overview

Around 90% of the drug candidates in the current development pipeline and close to 40% of marketed pharmacological products, have been associated with concerns related to solubility and / or permeability. In this context, considering modern regulatory standards, a large number of potential therapeutic leads fail to clear the clinical evaluation phase and enter the market, owing to poor bioavailability. Over time, innovators in the biopharmaceutical industry have developed a number of ways to improve / augment physiochemical properties and ultimately, the drug-like behavior of pharmacological substances. Amidst other alternatives, lipid nanoparticles and the use of various lipid-based excipients (which improve permeability across biological membranes), have garnered the attention of drug developers. In fact, the novel mRNA-based COVID-19 vaccines use lipid nanoparticles to deliver the active ingredient of the preventive intervention to the required site of action, which is within target antigen presenting cells in the human body. Moreover, many other companies are using the aforementioned lipid-based solutions to re-formulate existing product candidates in order to improve their bioavailability. As a result, the demand for lipid drug carriers and excipients has grown considerably. However, for some of the lipids that have medical applications, the associated manufacturing processes are highly complex, capital-intensive, and fraught with multiple challenges. Some of the major issues related to the production of GMP grade lipids include the need for specialized expertise (especially in the case of lipid nanoparticles), lack of facilities with the necessary infrastructure and capacity to produce the required quality of substances, as well as concerns related to storage, safety and efficacy. 

Considering the technical and routine operations-related challenges, an increasing number of pharmaceutical companies have demonstrated the preference to outsource their respective lipid production operations to specialized service providers. The benefits of engaging CMOs for lipid manufacturing are numerous; for instance, contracting a supplier for medical grade lipids enables sponsors to leverage new technologies (available with the service provider), access larger capacities and achieve greater operational flexibility. Presently, there are several contract manufacturers and technology providers that claim to have the required capabilities to manufacture lipid-based drug delivery systems (such as liposomes / lipid nanoparticles) and lipid excipients. However, the global expertise and capabilities for producing GMP grade lipids is presently limited. As a result, many of the aforementioned companies are actively trying to consolidate their presence in this field, by entering into strategic alliances to broaden their respective service portfolios and lipid manufacturing capabilities. On the other hand, recently, a number of deals were inked between vaccine developers and CMOs in order to cater to the urgent need for lipid-based solutions for formers’ respective COVID-19 vaccines. Considering the benefits of using lipids to improve drug-like properties, we believe that the demand for high quality lipids is likely to drive commendable growth within the specialty contract manufacturing market in the coming years.

Scope of the Report

The ‘Lipid Contract Manufacturing Market by Type of Lipid (Liposomes / Lipid Nanoparticles, Phospholipids, Pegylated Lipids, Ionizable Lipids (Cationic / Anionic Lipids), Triglycerides, Sphingolipids, Neutral Lipids and Others), Company Size (Small, Mid-Sized and Large / Very Large), Scale Of Operation (Preclinical, Clinical and Commercial) and Key Geographical Regions (North America, Europe, Asia Pacific, MENA and Latin America and Rest Of The World): Industry Trends and Global Forecasts, 2021-2030’ report features an extensive study of the current market landscape and future potential of the lipid contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract service providers engaged in this domain. Amongst other elements, the report features:

  • A detailed review of the overall landscape of companies offering contract services for the manufacturing of lipids, along with information on their year of establishment, company size (in terms of employee count), scale of operation (preclinical, clinical and commercial), location of headquarters, location of manufacturing facilities, type of product (lipid-based FDF, lipid-based drug delivery system, lipid excipients and lipid-based API), type of service(s) offered (manufacturing, formulation development, process development / pre-formulation, analytical method development, scale-up, stability studies, regulatory support, fill / finish and packaging and other services) and type of lipid manufactured (liposomes / lipid nanoparticles, phospholipids, PEGylated lipids, ionizable lipids, triglycerides, sphingolipids, neutral lipids and others).
  • A competitiveness analysis of the lipid contract manufacturers, located in North America, Europe and Asia-Pacific, based on various relevant parameters, such as supplier power (based on the experience / expertise of the manufacturer) and service strength (based on number of service(s) offered, type of product(s) manufactured, number of manufacturing facilities, type of lipid manufactured and scale of operation).
  • An analysis of the partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021. The various types of partnerships captured in our study include (in alphabetical order) acquisitions, distribution agreements, manufacturing agreements, product development agreements, service alliances, supply agreements, technology licensing agreements and others. 
  • A detailed analysis of the recent expansions undertaken (since 2016) by various service providers for augmenting their respective lipid contract manufacturing service portfolios. The analysis is based on several relevant parameters, including year of expansion, type of expansion (capacity expansion, facility expansion and new facility), scale of operation (n terms of type of expansion), type of product,  amount invested, company size, location of headquarters, geographical location of the expanded facility, most active players (in terms of number of recent expansiosince) and geographical distribution (region-wise and country-wise) of the expansion activity.
  • An estimate of the global installed capacity for lipids, by taking into consideration the capacities of various lipid contract manufacturers. The chapter highlights the distribution of available global lipid production capacity based on various parameters, such as company size (small, mid-sized, large and very large companies), scale of operation (preclinical, clinical and commercial) and key geographical regions (North America, Europe, Asia-Pacific and rest of the world).
  • Elaborate profiles of prominent players (shortlisted based on a proprietary criterion) that offer various lipid manufacturing services, across North America, Europe and Asia-Pacific. Each profile provides an overview of the company, its financial performance (if available), details related to its service portfolio, manufacturing facilities, recent developments, and an informed future outlook. 
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by lipid developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A case study on the wide adoption of lipids as drug delivery systems in mRNA vaccines. It also provides a list of various technology developers for formulating lipid-based formulations and lipid-based / liposomal drugs that are approved by the FDA till date.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the lipid contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of lipid (liposomes / lipid nanoparticles, phospholipids, PEGylated lipids, ionizable lipids (cationic / anionic lipids), triglycerides, sphingolipids, neutral lipids and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical, clinical and commercial) and [D] key geographical regions (North America, Europe, Asia-Pacific, MENA, Latin America and rest of the world).  To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Asha Van Rooijen (Founder and Chief Executive Officer, Liposoma)
  • Rahul Keswani (Associate Director, Formulation Development, Exelead)
  • John Riley (Director, Process Development-Chemistry, BioVectra) and Clement Mugabe (Acting Manager, Biotech Process Development, BioVectra) 

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading lipid contract manufacturers engaged in this domain?
  • Which global regions are considered as key hubs for contract manufacturing of lipid products?
  • What type of partnership models are commonly adopted by stakeholders in this industry?
  • What different expansion initiatives have been undertaken by lipid contract manufacturers? 
  • Which factors are likely to influence the decision of lipid manufacturing being done in-house or outsourced?
  • What is current, global lipid manufacturing capacity (in litres) of contract manufacturers?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the likely evolution of the lipid contract manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general overview of the lipids, featuring information on the various types and applications of lipids in the pharmaceutical industry. Additionally, it includes information on the challenges related to manufacturing of lipid-based formulations. It also features a discussion on the growing need for outsourcing the manufacturing of such products.

Chapter 4 provides an overview of the overall lipid contract manufacturing landscape. It includes information on close to 60 contract manufacturers currently engaged in this domain. Additionally, it features an in-depth analysis of service providers, based on a number of relevant parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, location of lipid manufacturing facilities, type of product (lipid-based FDF, lipid-based drug delivery system, lipid excipients and lipid-based API), type of lipids manufactured (liposomes / lipid nanoparticles, phospholipids, PEGylated lipids, ionizable lipids, triglycerides, sphingolipids, neutral lipids and others) and include details on type of services offered (manufacturing, formulation development, process development / pre-formulation, analytical method development, scale-up, stability studies, regulatory support, fill / finish and packaging and other services).

Chapter 5 features a detailed competitiveness analysis of the lipid contract manufacturers, located in North America, Europe and Asia-Pacific, based on various relevant parameters, such as supplier power (based on the experience / expertise of the manufacturer), and service strength (based on number of service(s) offered, type of product(s) manufactured, number of manufacturing facilities, type of lipids manufactured and scale of operation).

Chapter 6 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in the lipid contract manufacturing market in North America. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on recent developments, as well as an informed future outlook.

Chapter 7 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in the lipid contract manufacturing market in Europe. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on recent developments, as well as an informed future outlook.

Chapter 8 provides detailed profiles of the prominent players (shortlisted based on a proprietary criterion) that are active in the lipid contract manufacturing market in Asia-Pacific. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on recent developments, as well as an informed future outlook.

Chapter 9 features an analysis of the various collaborations and partnerships that have been inked by stakeholders engaged in this domain, during the period 2016-2021. It includes a brief description of the partnership models (including acquisitions, distribution agreements, manufacturing agreements, product development agreements, service alliances, supply agreements, technology licensing agreements and others) adopted by stakeholders in this domain. Further, it comprises of analysis based on year of agreement, type of agreement,  type of product, focus area and most active player(s) (in terms of number of partnerships inked). Further, the chapter includes a world map representation of all the deals inked in this field in the period 2016-2021, highlighting both intercontinental and intracontinental partnership activity.

Chapter 10 presents a detailed analysis of the recent expansions undertaken (since 2016) by various contract manufacturers to enhance their capabilities, based on various parameters, including year of expansion, type of expansion (capacity expansion, facility expansion and new facility), geographical location of the facility, type of product, scale of operation (in terms of type of expansion). It also highlights the most active players (in terms of number of recent instances) in the domain and geographical distribution (region-wise and country-wise) of the expansion activity.

Chapter 11 features a comprehensive analysis of the global / regional capacity of the contract manufacturers that are engaged in the manufacturing of lipids. The analysis takes into consideration the individual manufacturing capacities of various stakeholders (small, mid-sized, large and very large CMOs) in the market, using data from both secondary and primary research. Further, the chapter also examines the likely distribution of the global lipid manufacturing capacity available across different types of companies (small, mid-sized, large and very large CMOs), scales of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia-Pacific, and rest of the world).

Chapter 12 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by lipid developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMOs.

Chapter 13 presents an insightful market forecast analysis, highlighting the likely growth of the lipid contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] type of lipid (liposomes / lipid nanoparticles, phospholipids, PEGylated lipids, ionizable lipids (cationic / anionic lipids), triglycerides, sphingolipids, neutral lipids and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical, clinical and commercial) and [D] key geographical regions (North America, Europe, Asia-Pacific, MENA and Latin America and rest of the world).

Chapter 14 is a case study on the wide adoption of lipids as drug delivery systems in mRNA vaccines. It also provides a list of various technology developers for formulating lipid-based formulations and lipid-based / liposomal drugs that are approved by the FDA till date.

Chapter 15 summarizes the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 16 provides the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the lipid contract manufacturing domain. In this chapter, we have presented the details of our conversation with Asha Van Rooijen (Founder and Chief Executive Officer, Liposoma), Rahul Keswani (Associate Director, Formulation Development, Exelead), John Riley (Director, Process Development-Chemistry, BioVectra) and Clement Mugabe (Acting Manager, Biotech Process Development, BioVectra)

Chapter 17 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Lipids
3.2.1. Types of Lipids
3.3. Applications of Lipids in Pharmaceutical Industry
3.4. Challenges Associated with Lipid Manufacturing
3.5. Need for Outsourcing Lipid Manufacturing
3.6. Concluding Remarks

4. COMPETITIVE LANDSCAPE
4.1. Chapter Overview
4.2. Lipid Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Lipid Manufacturing Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Service(s) Offered
4.2.8. Analysis by Types of Lipids Manufactured
4.2.8.1. Analysis by Types of Lipids Manufactured and Company Size
4.2.8.2. Analysis by Types of Lipids Manufactured and Scale of Operation
4.2.8.3. Analysis by Types of Lipids Manufactured and Location of Headquarters

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Parameters
5.3. Methodology
5.4 Lipid Contract Manufacturers: Company Competitiveness Analysis
5.4.1. Company Competitiveness Analysis: Lipid Contract Manufacturers in North America
5.4.2. Company Competitiveness Analysis: Lipid Contract Manufacturers in Europe
5.4.3. Company Competitiveness Analysis: Lipid Contract Manufacturers in Asia-Pacific

6. COMPANY PROFILES: LIPID CONTRACT MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Avanti Polar Lipids
6.2.1. Company Overview
6.2.2. Lipid Manufacturing Service Offerings
6.2.3. Manufacturing Facilities
6.2.4. Recent Developments and Future Outlook

6.3. Creative Biolabs
6.3.1. Company Overview
6.3.2. Lipid Manufacturing Service Offerings
6.3.3. Manufacturing Facilities
6.3.4. Recent Developments and Future Outlook

6.4. Exelead
6.4.1. Company Overview
6.4.2. Lipid Manufacturing Service Offerings
6.4.3. Manufacturing Facilities
6.4.4. Recent Developments and Future Outlook

6.5. FormuMax Scientific
6.5.1. Company Overview
6.5.2. Lipid Manufacturing Service Offerings
6.5.3. Manufacturing Facilities
6.5.4. Recent Developments and Future Outlook

6.6. T&T Scientific
6.6.1. Company Overview
6.6.2. Lipid Manufacturing Service Offerings
6.6.3. Manufacturing Facilities
6.6.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: LIPID CONTRACT MANUFACTURERS IN EUROPE
7.1. Chapter Overview
7.2. Ardena
7.2.1. Company Overview
7.2.2. Lipid Manufacturing Service Offerings
7.2.3. Manufacturing Facilities
7.2.4. Recent Developments and Future Outlook

7.3. CordenPharma
7.3.1. Company Overview
7.3.2. Lipid Manufacturing Service Offerings
7.3.3. Manufacturing Facilities
7.3.4. Recent Developments and Future Outlook

7.4. Evonik
7.4.1. Company Overview
7.4.2. Lipid Manufacturing Service Offerings
7.4.3. Manufacturing Facilities
7.4.4. Recent Developments and Future Outlook

7.5. Fresenius Kabi
7.5.1. Company Overview
7.5.2. Lipid Manufacturing Service Offerings
7.5.3. Manufacturing Facilities
7.5.4. Recent Developments and Future Outlook

7.6. Merck KGaA
7.6.1. Company Overview
7.6.2. Lipid Manufacturing Service Offerings
7.6.3. Manufacturing Facilities
7.6.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: LIPID CONTRACT MANUFACTURERS IN ASIA-PACIFIC
8.1. Chapter Overview
8.2. Fujifilm
8.2.1. Company Overview
8.2.2. Lipid Manufacturing Service Offerings
8.2.3. Manufacturing Facilities
8.2.4. Recent Developments and Future Outlook

8.3. Nagase Medicals
8.3.1. Company Overview
8.3.2. Lipid Manufacturing Service Offerings
8.3.3. Manufacturing Facilities
8.3.4. Recent Developments and Future Outlook

8.4. Nippon Fine Chemical
8.4.1. Company Overview
8.4.2. Lipid Manufacturing Service Offerings
8.4.3. Manufacturing Facilities
8.4.4. Recent Developments and Future Outlook

8.5. TTY Biopharm
8.5.1. Company Overview
8.5.2. Lipid Manufacturing Service Offerings
8.5.3. Manufacturing Facilities
8.5.4. Recent Developments and Future Outlook

8.6. VCARE Bio Labs
8.6.1. Company Overview
8.6.2. Lipid Manufacturing Service Offerings
8.6.3. Manufacturing Facilities
8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Lipid Contract Manufacturing Market: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Type of Product
9.3.4. Analysis by Type of Focus Area
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Geographical Analysis
9.3.6.1. Region-wise Distribution
9.3.6.2. Country-wise Distribution

10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Lipid Contract Manufacturing Market: Recent Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Expansion and Scale of Operation
10.2.4. Analysis by Type of Product
10.2.5. Analysis by Amount Invested
10.2.6. Analysis by Company Size and Location of Headquarters
10.2.7. Analysis by Location of Expanded Facility
10.2.8. Most Active Players: Analysis by Number of Recent Expansions
10.2.9. Geographical Analysis
10.2.9.1. Region-wise Distribution
10.2.9.2. Country-wise Distribution

11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Lipid Contract Manufacturing: Installed Global Capacity (Million Liters)
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks

12. MAKE VERSUS BUY DECISION MAKING FRAMEWORK
12.1. Chapter Overview
12.2. Assumptions and Parameter Definitions
12.3. Lipid Contract Manufacturing: Make Versus Buy Decision Making
12.3.1. Scenario 1
12.3.2. Scenario 2
12.3.3. Scenario 3
12.3.4. Scenario 4
12.4. Concluding Remarks

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Lipid Contract Manufacturing Market, 2021-2030
13.4. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Type of Lipid
13.5. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Company Size
13.6. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Scale of Operation
13.7. Lipid Contract Manufacturing Market, 2021-2030: Distribution by Region
13.7.1. Lipid Contract Manufacturing Market in North America, 2021-2030
13.7.2. Lipid Contract Manufacturing Market in Europe, 2021-2030
13.7.3. Lipid Contract Manufacturing Market in Asia-Pacific, 2021-2030
13.7.4. Lipid Contract Manufacturing Market in MENA, 2021-2030
13.7.5. Lipid Contract Manufacturing Market in Latin America, 2021-2030
13.7.6. Lipid Contract Manufacturing Market in Rest of the World, 2021-2030

14. CASE STUDY: APPLICATIONS OF LIPIDS AND LIPID FORMULATION TECHNOLOGIES
14.1. Chapter Overview
14.2. Biopharmaceutical Drug Classification System
14.3. Lipid-based Formulations as Drug Delivery Systems
14.3.1. Role of Lipids in mRNA Vaccines
14.3.2. Recent Developments in Lipid Nanoparticles
14.4. Lipid-based Formulation Technology Developers
14.4.1. Analysis by Year of Establishment
14.4.2. Analysis by Company Size
14.4.3. Analysis by Location of Headquarters

15. CONCLUDING REMARKS

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Liposoma
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Asha Van Rooijen, Founder and CEO

16.3. Exelead
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Rahul Keswani, Associate Director, Formulation Development

16.4. BioVectra
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Clement Mugabe, Acting Manager, Biotech Process Development and John Riley, Director, Process Development – Chemistry

17. APPENDIX 1: TABULATED DATA

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Applications of Lipid-based Formulations
Figure 3.2 Classification of Lipids
Figure 4.1 Lipid Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Lipid Contract Manufacturers: Distribution by Company Size
Figure 4.3 Lipid Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Lipid Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Lipid Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Lipid Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Figure 4.7 Lipid Contract Manufacturers: Distribution by Location of Lipid Manufacturing Facilities (Region-wise)
Figure 4.8 Lipid Contract Manufacturers: Distribution by Location of Lipid Manufacturing Facilities (Country-wise)
Figure 4.9 Lipid Contract Manufacturers: Distribution by Type of Product
Figure 4.10 Lipid Contract Manufacturers: Distribution by Service(s) Offered
Figure 4.11 Lipid Contract Manufacturers: Distribution by Type of Product and Service(s) Offered
Figure 4.12 Lipid Contract Manufacturers: Distribution by Service(s) Offered and Location of Headquarters
Figure 4.13 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured
Figure 4.14 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured and Company Size
Figure 4.15 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured and Scale of Operation
Figure 4.16 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured and Location of Headquarters
Figure 5.1 Company Competitiveness Analysis: Lipid Contract Manufacturers in North America
Figure 5.2 Company Competitiveness Analysis: Lipid Contract Manufacturers in Europe
Figure 5.3 Company Competitiveness Analysis: Lipid Contract Manufacturers in Asia-Pacific
Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 9.5 Partnerships and Collaborations: Year-wise Trend by Type of Product, 2016-2021
Figure 9.6 Partnerships and Collaborations: Distribution by Type of Focus Area
Figure 9.7 Most Active Players: Distribution by Number of Partnerships
Figure 9.8 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Figure 9.9 Partnerships and Collaborations: Distribution by Region (Country-wise)
Figure 10.1 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Type of Expansion and Scale of Operation
Figure 10.4 Recent Expansions: Distribution by Type of Product
Figure 10.5 Recent Expansions: Distribution by Type of Expansion and Type of Product
Figure 10.6 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 10.7 Recent Expansions: Distribution by Company Size and Location of Headquarters
Figure 10.8 Recent Expansions: Distribution by Location of Expanded Facility
Figure 10.9 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Figure 10.10 Most Active Players: Distribution by Number of Recent Expansions
Figure 10.11 Recent Expansions: Distribution by Year of Expansion and Region
Figure 10.12 Recent Expansions: Distribution by Region (Country-wise)
Figure 11.1. Lipid Contract Manufacturing Capacity: Distribution by Company Size
Figure 11.2. Lipid Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 11.3. Lipid Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 12.1. Make versus Buy Decision Making Framework
Figure 12.2. Make versus Buy Decision Making: Description of Possible Scenarios
Figure 13.1 Global Lipid Contract Manufacturing Market, 2021-2030 (USD Billion)
Figure 13.2 Lipid Contract Manufacturing Market, 2021-2030: Distribution by Type of Product (USD Billion)
Figure 13.3 Lipid Contract Manufacturing Market, 2021-2030: Distribution by Company Size (USD Billion)
Figure 13.4 Lipid Contract Manufacturing Market, 2021-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.5 Lipid Contract Manufacturing Market in North America, 2021-2030 (USD Billion)
Figure 13.6 Lipid Contract Manufacturing Market in Europe, 2021-2030 (USD Billion)
Figure 13.7 Lipid Contract Manufacturing Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 13.8 Lipid Contract Manufacturing Market in MENA, 2021-2030 (USD Billion)
Figure 13.9 Lipid Contract Manufacturing Market in Latin America, 2021-2030 (USD Billion)
Figure 13.10 Lipid Contract Manufacturing Market in Rest of the World, 2021-2030 (USD Billion)
Figure 14.1 Biopharmaceutics Classification System (BCS)
Figure 14.2 Types of Lipid-based Drug Delivery Systems
Figure 14.3 Lipid-based mRNA Vaccines: Mechanism of Action
Figure 15.1 Concluding Remarks: Overall Market Landscape
Figure 15.2 Concluding Remarks: Partnerships and Collaborations
Figure 15.3 Concluding Remarks: Recent Expansions
Figure 15.4 Concluding Remarks: Capacity Analysis
Figure 15.5 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 List of Lipid Contract Manufacturers
Table 4.2 Lipid Contract Manufacturers: Information on Number and Location of Manufacturing Facilities
Table 4.3 Lipid Contract Manufacturers: Information on Type of Product and Scale of Operation
Table 4.4 Lipid Contract Manufacturers: Information on Service(s) Offered
Table 4.5 Lipid Contract Manufacturers: Information on Types of Lipids Manufactured
Table 6.1 Lipid Contract Manufacturers: List of Profiled Companies (North America)
Table 6.2 Avanti Polar Lipids: Company Snapshot
Table 6.3 Avanti Polar Lipids: Lipid-related Service Offerings
Table 6.4 Avanti Polar Lipids: Information on Manufacturing Facility
Table 6.5 Avanti Polar Lipids: Recent Developments and Future Outlook
Table 6.6 Creative Biolabs: Company Snapshot
Table 6.7 Creative Biolabs: Lipid-related Service Offerings
Table 6.8 Creative Biolabs: Information on Manufacturing Facility
Table 6.9 Exelead: Company Snapshot
Table 6.10 Exelead: Lipid-related Service Offerings
Table 6.11 Exelead: Information on Manufacturing Facility
Table 6.12 Exelead: Recent Developments and Future Outlook
Table 6.13 FormuMax Scientific: Company Snapshot
Table 6.14 FormuMax Scientific: Lipid-related Service Offerings
Table 6.15 FormuMax Scientific: Information on Manufacturing Facility
Table 6.16 T&T Scientific: Company Snapshot
Table 6.17 T&T Scientific: Lipid-related Service Offerings
Table 6.18 T&T Scientific: Information on Manufacturing Facility
Table 6.19 T&T Scientific: Recent Developments and Future Outlook
Table 7.1 Lipid Contract Manufacturers: List of Profiled Companies (Europe)
Table 7.2 Ardena: Company Snapshot
Table 7.3 Ardena: Lipid-related Service Offerings
Table 7.4 Ardena: Information on Manufacturing Facility
Table 7.5 Ardena: Recent Developments and Future Outlook
Table 7.6 CordenPharma: Company Snapshot
Table 7.7 CordenPharma: Lipid-related Service Offerings
Table 7.8 CordenPharma: Information on Manufacturing Facility
Table 7.9 CordenPharma: Recent Developments and Future Outlook
Table 7.10 Evonik: Company Snapshot
Table 7.11 Evonik: Lipid-related Service Offerings
Table 7.12 Evonik: Information on Manufacturing Facility
Table 7.13 Evonik: Recent Developments and Future Outlook
Table 7.14 Fresenius Kabi: Company Snapshot
Table 7.15 Fresenius Kabi: Lipid-related Service Offerings
Table 7.16 Fresenius Kabi: Information on Manufacturing Facility
Table 7.17 Fresenius Kabi: Recent Developments and Future Outlook
Table 7.18 Merck KGaA: Company Snapshot
Table 7.19 Merck KGaA: Lipid-related Service Offerings
Table 7.20 Merck KGaA: Information on Manufacturing Facility
Table 7.21 Merck KGaA: Recent Developments and Future Outlook
Table 8.1 Lipid Contract Manufacturers: List of Profiled Companies (Asia-Pacific)
Table 8.2 Fujifilm: Company Snapshot
Table 8.3 Fujifilm: Lipid-related Service Offerings
Table 8.4 Fujifilm: Information on Manufacturing Facility
Table 8.5 Fujifilm: Recent Developments and Future Outlook
Table 8.6 Nagase Medicals: Company Snapshot
Table 8.7 Nagase Medicals: Lipid-related Service Offerings
Table 8.8 Nagase Medicals: Information on Manufacturing Facility
Table 8.9 Nagase Medicals: Recent Developments and Future Outlook
Table 8.10 Nippon Fine Chemical: Company Snapshot
Table 8.11 Nippon Fine Chemical: Lipid-related Service Offerings
Table 8.12 Nippon Fine Chemical: Information on Manufacturing Facility
Table 8.13 TTY Biopharm: Company Snapshot
Table 8.14 TTY Biopharm: Lipid-related Service Offerings
Table 8.15 TTY Biopharm: Information on Manufacturing Facility
Table 8.16 TTY Biopharm: Recent Developments and Future Outlook
Table 8.17 VCARE Bio Labs: Company Snapshot
Table 8.18 VCARE Bio Labs: Lipid-related Service Offerings
Table 9.1 Lipid Contract Manufacturers: List of Partnerships and Collaborations, 2016-2021
Table 10.1 Lipid Contract Manufacturers: Recent Expansions, 2016-2021
Table 14.1 Lipid Formulation Technologies: List of Developers
Table 14.2 List of Approved Lipid-based Drugs
Table 17.1 Lipid Contract Manufacturers: Distribution by Year of Establishment
Table 17.2 Lipid Contract Manufacturers: Distribution by Company Size
Table 17.3 Lipid Contract Manufacturers: Distribution by Scale of Operation
Table 17.4 Lipid Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 17.5 Lipid Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 17.6 Lipid Contract Manufacturers: Distribution by Company Size and Location of Headquarters
Table 17.7 Lipid Contract Manufacturers: Distribution by Location of Lipid Manufacturing Facilities (Region-wise)
Table 17.8 Lipid Contract Manufacturers: Distribution by Location of Lipid Manufacturing Facilities (Country-wise)
Table 17.9 Lipid Contract Manufacturers: Distribution by Type of Product
Table 17.10 Lipid Contract Manufacturers: Distribution by Service(s) Offered
Table 17.11 Lipid Contract Manufacturers: Distribution by Type of Product and Service(s) Offered
Table 17.12 Lipid Contract Manufacturers: Distribution by Service(s) Offered and Location of Headquarters
Table 17.13 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured
Table 17.14 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured and Company Size
Table 17.15 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured and Scale of Operation
Table 17.16 Lipid Contract Manufacturers: Distribution by Types of Lipids Manufactured and Location of Headquarters
Table 17.17 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2021
Table 17.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.19 Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 17.20 Partnerships and Collaborations: Distribution by Type of Product
Table 17.21 Partnerships and Collaborations: Year-wise Trend by Type of Product, 2016-2021
Table 17.22 Partnerships and Collaborations: Distribution by Type of Focus Area
Table 17.23 Most Active Players: Distribution by Number of Partnerships
Table 17.24 Partnerships and Collaborations: Distribution by Region (Continent-wise)
Table 17.25 Partnerships and Collaborations: Distribution by Region (Country-wise)
Table 17.26 Recent Expansions: Cumulative Year-wise Trend, 2016-2021
Table 17.27 Recent Expansions: Distribution by Type of Expansion
Table 17.28 Recent Expansions: Distribution by Type of Expansion and Scale of Operation
Table 17.29 Recent Expansions: Distribution by Type of Product
Table 17.30 Recent Expansions: Distribution by Type of Expansion and Type of Product
Table 17.31 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 17.32 Recent Expansions: Distribution by Company Size and Location of Headquarters
Table 17.33 Recent Expansions: Distribution by Location of Expanded Facility
Table 17.34 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 17.35 Most Active Players: Distribution by Number of Recent Expansions
Table 17.36 Recent Expansions: Distribution by Year of Expansion and Region
Table 17.37 Recent Expansions: Distribution by Region (Country-wise)
Table 17.38 Lipid Contract Manufacturing Capacity: Distribution by Company Size
Table 17.39 Lipid Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 17.40 Lipid Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 17.41 Global Lipid Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 17.42 Lipid Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Type of Product (USD Billion)
Table 17.43 Lipid Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Company Size (USD Billion)
Table 17.44 Lipid Contract Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Distribution by Scale of Operation (USD Billion)
Table 17.45 Lipid Contract Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 17.46 Lipid Contract Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 17.47 Lipid Contract Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 17.48 Lipid Contract Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 17.49 Lipid Contract Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)
Table 17.50 Lipid Contract Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 2-BBB Medicines
  2. Abbott Laboratories
  3. AbbVie Contract Manufacturing
  4. ABITEC
  5. ADM-SIO
  6. Ajinomoto Bio-Pharma Services
  7. Alnylam Pharmaceuticals
  8. Althea Technologies
  9. Altum Pharmaceuticals
  10. Amatsigroup
  11. AmpTec
  12. AMRI
  13. Arbro Pharmaceuticals
  14. Arbutus Biopharma
  15. Arcturus Therapeutics
  16. Ardena
  17. Aronex Pharmaceuticals (a subsidiary of Agenus)
  18. Ascendia Pharmaceuticals
  19. Astellas Pharma
  20. Avanti Polar Lipids
  21. B. Braun
  22. BASF
  23. Bausch Health (formerly Valeant Pharmaceuticals)
  24. Bayer
  25. Berna Biotech Pharma
  26. Biochempeg
  27. BioConnection
  28. BioNTech
  29. Bioserv 
  30. BioVectra
  31. BioZone Labs
  32. BOC Sciences
  33. Boehringer Ingelheim
  34. Bristol Myers Squibb
  35. Britannia Pharmaceuticals
  36. BSP Pharmaceuticals
  37. Caisson Biotech
  38. Camurus
  39. CanSino Biologics
  40. Capsugel
  41. Catalent
  42. Cayman Chemical
  43. ChemConnection
  44. Cipher Pharmaceuticals
  45. Cone Bioproducts
  46. CordenPharma
  47. Creative Biolabs
  48. Creative Biostructure
  49. Croda
  50. Crucell
  51. CuriRx
  52. Daiichi Sankyo
  53. Dalton Pharma Services
  54. Diethelm Keller Siber Hegner (DKSH)
  55. DSM
  56. Eisai
  57. Elan Pharmaceuticals
  58. Empirical Labs
  59. Encapsula NanoSciences
  60. Entos Pharmaceuticals
  61. Evonik
  62. Exelead
  63. ForDoz Pharma
  64. FormuMax Scientific
  65. Fresenius Kabi
  66. Fujifilm
  67. Gattefossé
  68. Genus Pharmaceuticals (acquired by STADA Arzneimittel)
  69. Genzyme
  70. GHO Capital
  71. GlaxoSmithKline
  72. Glenmark Pharmaceuticals
  73. GP Pharm
  74. Helix BioPharma
  75. HTD Biosystems
  76. IMCD
  77. Intas Pharmaceuticals
  78. Jamia Hamdard University
  79. Jazz Pharmaceuticals
  80. Jina Pharmaceuticals
  81. Juniper Pharmaceuticals (acquired by Catalent)
  82. KD Pharma
  83. Keystone Nano
  84. Kowa Pharmaceuticals
  85. Kuecept
  86. Lantheus Medical Imaging
  87. Larodan
  88. LATITUDE Pharmaceuticals
  89. Leadiant Biosciences
  90. Lipid Systems
  91. Lipidome Lifesciences
  92. Lipoid
  93. LipoMedix
  94. Lipomize
  95. LIPOSOMA
  96. lndchem International
  97. Lonza
  98. LSNE Contract Manufacturing
  99. Lubrizol
  100. Lupin
  101. Lypro Biosciences
  102. Marine Ingredients (KD Pharma)
  103. Matinas BioPharma
  104. Matreya
  105. Memory Secret
  106. Merck
  107. Merrimack Pharmaceuticals
  108. Micro-Sphere
  109. MIKA PHARMACEUTICALS
  110. Moderna
  111. Moleculin Biotech
  112. Nabros Pharma
  113. Nagase Medicals
  114. NattoPharma
  115. Nemus Bioscience
  116. NeXstar Pharmceuticals (acquired by Gilead Sciences)
  117. NextPharma
  118. Nippon Fine Chemical
  119. NOF Europe
  120. Novartis
  121. Novavax
  122. OPKO Health
  123. Organon
  124. Ozone Pharmaceuticals
  125. Pacira Pharmaceuticals
  126. Pfizer
  127. Phares Drug Delivery
  128. Pharmaceutics International
  129. Pharmacia
  130. PharmaSol
  131. Phosphorex
  132. Piramal Pharma Solutions
  133. Polymun Scientific
  134. Precision NanoSystems
  135. Quay Pharma
  136. Quotient Sciences
  137. Regulon
  138. Roche
  139. Samyang Biopharmaceuticals
  140. Sancilio Pharmaceuticals
  141. Sanofi-Aventis
  142. Schering-Plough
  143. SciTech Development
  144. Sequus Pharmaceuticals
  145. Shochem (Shanghai)
  146. Sirnaomics
  147. SkyPharma
  148. SoluBest
  149. STA Pharmaceutical
  150. Sucampo Pharmaceuticals
  151. Sun Pharma
  152. Syntagon
  153. T&T Scientific
  154. Takeda Pharmaceuticals
  155. Talon Therapeutics
  156. Tergus Pharma
  157. Teva Pharmaceuticals
  158. The Liposome Company (acquired by Elan Pharmaceuticals)
  159. Transferra Nanosciences (acquired by Evonik)
  160. TTY Biopharm
  161. Univar Solutions
  162. Validus Pharmaceuticals
  163. Valimenta
  164. Variant Pharmaceuticals
  165. VAV Lifesciences
  166. VCARE Bio Labs
  167. Vesifact
  168. Vineland Environmental Laboratories
  169. ViralClear Pharmaceuticals (a subsidiary of BioSig)
  170. Vitasome
  171. VLP Therapeutics
  172. Wyeth Pharmaceuticals
  173. ZoneOne Pharma

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com